Biomarkers in Colorectal Cancer

Colorectal cancer remains one of the most frequently diagnosed cancers in the developed world. The advent of new therapeutic agents has further expanded our treatment options. Epidermal growth factor receptor (EGFR) inhibitors have been shown to improve survival in metastatic cancer. However, there remain a substantial proportion of patients who do not benefit from this treatment. KRAS mutation status has been validated to predict the response to EGFR inhibitors with mutant status predicting non-responders. The validation of other predictive and prognostic markers will result in further optimization of the care plan for patient with colorectal cancer; maximising benefits while minimising toxicities. This article aims to provide an update of the various molecular markers for use in detection, prognostication and predicting responses in colon cancer